



March 15, 2017

The General Manager  
Department of Corporate Services  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

Dear Sir

Subject: unaudited Quarterly Results – Clause 33 of Listing Regulations,  
2015.

We are enclosing hereto the unaudited quarterly results for the quarter ended ended 31<sup>st</sup> December 2016 in terms of Clause 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Which may kindly be taken on record.

Thanking you

Yours Sincerely  
For TRANSGENE BIOTEK LIMITED

A handwritten signature in blue ink, appearing to read 'Dr. K. Koteswara Rao', is written over a horizontal line.

DR K KOTESWARA RAO  
CHAIRMAN & MANAGING DIRECTOR

Encls: as above

**TRANSGENE BIOTEK LIMITED**  
68,69,&70, ANRICH INDUSTRIAL AREA  
BOLLARAM, MEDAK DISTRICT

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31.12.2016**


(Rs. In Lakhs)

Particulars	Quarter ended 30.12.2016	Quarter ended 30.09.2016	Quarter ended 30.12.2015	Year to date figures for the current period ended 31.12.2016	Year to date figures for the previous period ended 31.12.2015	For Previous year ended 31.03.2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 (a) Net Sales/Income from Operations	14.50	5.24	11.83	23.65	26.13	34.98
(b) Other Operating Income	-	-	-	-	-	-
<b>2. Expenditure</b>						
a. Increase/decrease in stock in trade and work in progress	-	-	-	-	-	-
b. Consumption of raw materials	-	-	-	-	-	0.08
c. Purchase of traded goods	-	-	-	-	-	-
d. Employees cost	14.48	14.34	18.01	43.44	53.28	68.15
e. Depreciation	506.82	496.53	687.68	1,505.35	1,550.97	2,050.23
f. Other expenditure	16.06	10.93	20.06	38.68	50.31	63.05
<b>Total</b>	<b>537.36</b>	<b>521.79</b>	<b>725.75</b>	<b>1,587.47</b>	<b>1,654.56</b>	<b>2,181.51</b>
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	-522.86	-516.55	-713.92	-1,563.82	-1,628.43	-2,146.53
4 Other Income	-	-	-	-	-	-
5 Profit / (loss) from Ordinary activities before finance cost and exceptional items(3+4)	<b>-522.86</b>	<b>-516.55</b>	<b>-713.92</b>	<b>-1,563.82</b>	<b>-1,628.43</b>	<b>-2,146.53</b>
6 Finance Cost	0.01	0.06	0.02	0.09	0.15	7.31
7 Profit / (loss) from ordinary activities after finance cost but before Exceptional Items (5-6)	-522.87	-516.61	-713.94	-1,563.91	-1,628.58	-2,153.84
8 Prior Period Expenses/ (income)	-	-	-	-	-	-
9 Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	-522.87	-516.61	-713.94	-1,563.91	-1,628.58	-2,153.84
10 Tax expense	-	-	-	-	-	-
11 Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	-522.87	-516.61	-713.94	-1,563.91	-1,628.58	-2,153.84
12 Extraordinary Item (net of tax expense if any)	-	-	-	-	-	-
13 <b>Net Profit(+)/ Loss(-) for the period (11-12)</b>	<b>-522.87</b>	<b>-516.61</b>	<b>-713.94</b>	<b>-1,563.91</b>	<b>-1,628.58</b>	<b>-2,153.84</b>
14 Share of profit/(loss) of associates	-	-	-	-	-	-
15 Minority Interest	-	-	-	-	-	-
16 <b>Net Profit(+)/ Loss(-) after taxes,Minority interest and share of profit/(Loss) of associates (13-14-15))</b>	<b>-522.87</b>	<b>-516.61</b>	<b>-713.94</b>	<b>-1,563.91</b>	<b>-1,628.58</b>	<b>-2,153.84</b>
17 Paid-up equity share capital (Face value of share of Rs 10/- each)	7,577.00	7,577.00	7,577.00	7,577.00	7,577.00	7,577.00
No of Shares	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000	75,770,000
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	6,324.97	6,847.85	8,403.23	6,324.97	8,403.23	7,888.89
<b>Earnings Per Share (EPS)</b>						
19 a) Basic EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.07	-0.07	-0.94	-2.06	-2.15	-2.84
b) Diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.07	-0.07	-0.94	-2.06	-2.15	-2.84
c) Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.07	-0.07	-0.94	-2.06	-2.15	-2.84
d) Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	-0.07	-0.07	-0.94	-2.06	-2.15	-2.84
<b>Public Shareholding</b>						
20 No. of shares	59,342,098	59,342,098	59,342,098	59,342,098	59,342,098	59,342,098
Percentage of shareholding	78.32	78.32	78.32	78.32	78.32	78.32
<b>Promoters and promoter group Shareholding **</b>	<b>16,427,902</b>	<b>16,427,902</b>	<b>16,427,902</b>	<b>16,427,902</b>	<b>16,427,902</b>	<b>16,427,902</b>
a) Pledged/Encumbered	-	-	-	-	-	-
Number of shares	-	-	-	-	-	-
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
21 Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non-encumbered						
Number of Shares	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902	16,427,902
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage of shares (as a % of the total share capital of the company)	21.68	21.68	21.68	21.68	21.68	21.68

**Notes to the Results**

- 1) Because of the Chairman of Board of Directors, Managing Director and Compliance officer of the company falling ill suddenly, the scheduled board meeting and consequent actions related to the statutory compliances for the quarter have been delayed and notified to BSE accordingly in time.
- 2) Contract R&D work is being taken up by the company on different bio-pharmaceuticals.
- 3) Developmental work is in progress for a new API and it is expected to be completed during the next quarter.
- 4) Discussions and relevant work on oral delivery of insulin analogue have reached the expected milestone. Further details can not be disclosed because of confidentiality agreement.
- 5) No. of Investor complaints pending at the beginning of the quarter - NIL; received during the quarter - NIL; resolved during the quarter - NIL; pending unresolved at the end of the quarter - NIL.
- 6) The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 15th March 2017.

Place: Hyderabad  
Date: 15.03.2017



**For TRANSGENE BIOTEK LTD**


*[Signature]*  
Managing Director

**Annexure IV to Clause 41**  
**Reporting of Segment wise Revenue, Results and Capital Employed along with the quarterly results**

(Rs. In Lakhs)

S.No	PARTICULARS	Quarter Ended 31.12.2016 (Unaudited)	Quarter Ended 30.09.2016 (Unaudited)	Quarter Ended 31.12.2015 (Unaudited)	Year to date figures for the current period ended 31.12.2016 (Unaudited)	Year to date figures for the previous period ended 31.12.2015 (Unaudited)	Previous year Ended 31.03.2016 (Audited)
1	<b>SEGMENT REVENUE</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>
	a)Segment -A Diagnostic Services	1.10	3.66	4.87	6.91	15.07	18.08
	b)Segment -B Agri Division	-	-	-	-	-	-
	c) Segment-C Bulk Drugs Trading	-	-	-	-	-	-
	d)Segment-D CRO Services	12.50	-	-	12.50	-	-
	e) Segment-E API-DHA	-	-	-	-	-	-
	f) Segment-F Others	0.90	1.58	6.96	4.24	11.06	16.91
	Total:	14.50	5.24	11.83	23.65	26.13	34.98
	Less: Inter Segement Revenue	-	-	-	-	-	-
	<b>Net Sales/income From Operation</b>	<b>14.50</b>	<b>5.24</b>	<b>11.83</b>	<b>23.65</b>	<b>26.13</b>	<b>34.98</b>
2	<b>SEGMENT RESULTS</b>						
	(Profit /Loss Before Tax & Interst from each Segment)						
	a)Segment -A Diagnostic services	-0.05	0.71	0.88	0.72	1.45	0.49
	b)Segment -B Agri Division	-	-	-	-	-	-
	c) Segment-C Bulk Drugs Trading	-	-	-	-	-	-
	d)Segment-D CRO Services	-	-	-	-	-	-
	e) Segment-E API-DHA	-	-	-	-	-	-
	f) Segment-F Other Unallocated	-522.48	-517.26	-714.78	-1,564.20	-1,629.70	-2,146.81
	g) R & D Expenses	-0.34	-	-0.02	-0.35	-0.17	-0.23
	<b>Total Segmental Result</b>	<b>-522.87</b>	<b>-516.55</b>	<b>-713.92</b>	<b>-1,563.83</b>	<b>-1,628.43</b>	<b>-2,146.54</b>
	Other Income	-	-	-	-	-	-
	<b>Total</b>	<b>-522.87</b>	<b>-516.55</b>	<b>-713.92</b>	<b>-1,563.83</b>	<b>-1,628.43</b>	<b>-2,146.54</b>
	Less: Interest & Finance Charges	0.00	0.06	0.02	0.08	0.15	7.30
	Less:Unallocable expenses	-	-	-	-	-	-
	Exceptional items-forex fluctuation( gain)/Loss	-	-	-	-	-	-
	<b>Total Profit/Loss Before Tax</b>	<b>-522.87</b>	<b>-516.61</b>	<b>-713.94</b>	<b>-1,563.91</b>	<b>-1,628.58</b>	<b>-2,153.84</b>
3	<b>CAPITAL EMPLOYED</b>						
	a)Segment - A Diagnostic services	324.83	324.83	324.83	324.83	324.83	324.83
	b)Segment - B Agri Division	-	-	-	-	-	-
	c) Segment-C Bulk Drugs	24,090.93	24,090.93	24,090.93	24,090.93	24,090.93	24,090.93
	Total	24,415.76	24,415.76	24,415.76	24,415.76	24,415.76	24,415.76

Place: Hyderabad  
Date: 15.03.2017



**TRANSGENE BIOTEK LTD.**

*[Signature]*

**Managing Director**



## ANNEXURE IX TO CLAUSE 41

(Rs. In Lacs)

Standalone Statement of Assets and Liabilities		As at Period ended 31st Dec 2016	As at Year ended 31st Mar 2016
		(Unaudited)	(Audited)
<b>A EQUITY AND LIABILITIES</b>			
1	Share Holders Fund		
	(a) Share Capital	7,577.00	7,577.00
	(b) Reserves and Surplus	6,324.97	7,888.89
	(c) Money Received against Share Warrants	-	-
	<b>Sub Total - Share Holders' Fund</b>	<b>13,901.97</b>	<b>15,465.89</b>
2	Share Application Money pending allotment	-	-
3	Minority Interest	-	-
4	Non-Current Liabilities		
	(a) Long Term Borrowings	633.84	633.84
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long-Term Liabilities	-	-
	(d) Long-term Provisions	12,087.86	12,087.86
	Sub-Total- Non Current Liabilities	12,721.70	12,721.70
5	Current Liabilities		
	(a) Short Term Borrowings	908.17	894.47
	(b) Trade Payables	84.26	84.47
	(c) Other Current Liabilities	188.61	142.13
	(d) Short-term Provisions	-	-
	<b>Sub-Total- Current Liabilities</b>	<b>1,181.04</b>	<b>1,121.07</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>27,804.71</b>	<b>29,308.66</b>
<b>B ASSETS</b>			
1	Non-Current Assets		
	(a) Fixed Assets	12,618.60	14,123.95
	(b) Goodwill on Consolidation	-	-
	(c) Non- Current Investments	9,220.10	9,220.10
	(d) Deferred Tax Assets (Net)	-	-
	(e) Long-term Loans and Advances	2,420.85	2,420.85
	(f) Other Non Current Assets	3,198.85	3,198.85
	<b>Sub - total -Non Current Assets</b>	<b>27,458.40</b>	<b>28,963.75</b>
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	6.54	6.54
	(c) Trade Receivables	164.27	162.64
	(d) Cash and Cash Equivalents	1.01	2.94
	(e) Short-term Loans and Advances	174.49	172.78
	(f) Other Current Assets	-	-
	<b>Sub-total- Current Assets</b>	<b>346.31</b>	<b>344.91</b>
	<b>TOTAL ASSETS</b>	<b>27,804.71</b>	<b>29,308.66</b>

Place: Hyderabad  
Date: 15.03.2017



For and on behalf of the Board of Directors

*Dr K Koteswara Rao*  
Dr K Koteswara Rao  
Chairman & Managing Director



**LIMITED REVIEW REPORT**

To,

**The Board of Directors  
M/s Transgene Biotek Limited  
Hyderabad**

1. We have reviewed the accompanying statements of unaudited financial result of **M/s Transgene Biotek Limited** for the quarter ended **31<sup>st</sup> December, 2016** except for the disclosures regarding 'Public Shareholding' and Promoter Group Shareholding' and 'Number of Investors Complaints' which have been traced from disclosures made by the management but have not audited by us. This statement has been prepared by the Company pursuant to clause 41 of the Listing Agreement with the Stock Exchange in India, which has been initialed by us for identification purpose. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Financial Statements are free of Material Misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-audited Financial results for the **Quarter ended 31<sup>st</sup> December, 2016** prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which is to be disclosed.

Place: Hyderabad.

Date: 15<sup>th</sup> March 2017.

GOPAL & RAJAN  
Chartered Accountants

K. GOUTHAM SUBBIAH

Partner

M.No.203237

FRN.000953S